Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation

J Crohns Colitis. 2018 Feb 28;12(3):376-378. doi: 10.1093/ecco-jcc/jjx141.

Abstract

A 35-year old woman with ileocolonic, perianal, and vulval Crohn's disease was treated with subcutaneous ustekinuamb [USK] throughout pregnancy. Dose intervals were shortened from 6-weekly to 4-weekly to maintain clinical remission. The last dose of USK was administered at 33 weeks of gestation, and a healthy baby boy was delivered by caesarean section at 37 weeks. Maternal trough USK levels remained stable during pregnancy. Cord blood USK levels were nearly 2-fold higher than contemporaneous maternal serum levels. To our knowledge, this is the first report of maternal and cord USK levels in a patient with Crohn's disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Crohn Disease / drug therapy*
  • Female
  • Fetal Blood / chemistry*
  • Gastrointestinal Agents / analysis
  • Gastrointestinal Agents / blood*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infant, Newborn
  • Male
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Ustekinumab / analysis
  • Ustekinumab / blood*
  • Ustekinumab / therapeutic use

Substances

  • Gastrointestinal Agents
  • Ustekinumab